SecBot SecBot

ENLV drug pipeline

Enlivex Ltd. · 1 rated drug
$1.15
+2.7% 1-day · Nov 17
Next catalyst
None dated
No dated FDA catalyst on file
Typical move on FDA news
No history
No past FDA events with prices
IV rank
No data
No current options data
Rated drugs
1
1 mixed
Phase 3 trials
0
0 with results posted

Drugs

soonest catalyst first
◆ mixed
Impact
PhasePhase 2b
Time to marketAt least 3-5 years if Phase 2b and subsequent Phase 3 trials succeed

Allocetra Updated Jul 7

What to watch

Allocetra's Phase 2a data in knee OA is intriguing (72% pain reduction in elderly patients), but the Phase 2b trial is only now starting enrollment with topline data not expected until mid-2027. Separately, ENLV's stock is heavily influenced by its RAIN token treasury (~$1.14B in tokens vs ~$127M market cap), this crypto overlay makes the stock more a prediction-markets proxy than a pure biotech play. Watch for Phase 2b enrollment updates and RAIN token price volatility.

Bull case
  • Knee OA is a massive market (~$314B longevity market) with NO approved disease-modifying drugs, current treatments are symptom only (painkillers, steroids, eventually joint replacement).
  • Phase 2a data was compelling: 72% pain reduction and 109% function improvement in age-related patients, with a 27.8-point pain reduction vs 15.5 for placebo (p=0.02), sustained at 6 months.
  • Allocetra has been studied in 150+ patients across indications with no serious adverse events reported, a clean safety profile for an off-the-shelf cell therapy.
Bear case
  • The Phase 2b trial is just entering enrollment; topline data is not expected until Q2-Q3 2027, meaning shareholders face 12+ months of binary-event-free time and likely further dilution.
  • The company has a history of heavy dilution: 252M shares outstanding pre-reverse split, a 1:15 reverse split announced July 2026 (often a negative signal), and a $21M convertible debt financing that adds dilution risk.
  • The RAIN token treasury valued at ~$1.14B is highly volatile and speculative, crypto token prices can collapse, and the company's market cap ($127M) being far below its treasury value signals deep investor skepticism.

Clinical trials

1 Phase 2/3
DrugTrialPhaseStatusEnrolledPrimary completion
AllocetraStudy of Intra-articular Allocetra in Knee OsteoarthritisPhase 2Completed134Mar 15, 2026